Heart Failure

An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

A recent survey of UK Biobank participants showed that healthy sleep habits were associated with a possible lower risk of heart failure among adults, even after adjusting for several confounders.

Dr. Anthony Fauci discusses the cardiovascular implications of coronavirus disease 2019 (COVID-19) at the American Heart Association Scientific Sessions.

After recent setbacks, the beleaguered drug reduced cardiovascular events and may be a choice for patients with severe chronic kidney disease.

A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.

Findings from the GALACTIC-HF trial presented at AHA Scientific Sessions 2020 showed that patients with heart failure (HF) with reduced ejection fraction who took omecamtiv mecarbil showed a significant 8% relative risk reduction in a composite of a HF event or death from cardiovascular causes, compared with those taking placebo.

Intravenous diuretic treatment of patients with decompensated heart failure can increase urine output, promote weight loss, and improve dyspnea.

Serum fatty acid–binding protein 4 levels were increased in patients with heart failure with preserved ejection fraction (HFpEF), associated with cardiac remodeling and dysfunction, and linked to poor outcomes.

Sarcopenic obesity is a condition in which obesity is accompanied by loss of muscle mass and function; the condition is common among older adults with heart failure with preserved ejection fraction (HFpEF).

The novel patient-centered performance metric was associated with readmission and mortality outcomes, as well as reclassification of hospital performance, compared with a CMS 30-day metric.

Study results demonstrate the multimillion-dollar savings achieved among patients with heart failure with reduced ejection fraction (HFrEF) following treatment initiation with sacubitril and valsartan.

Heart failure with reduced ejection fraction (HFrEF) is when the heart’s left ventricle can only pump out 40% or less of the blood it contains, resulting in less oxygen-rich blood being disseminated to the body than it actually needs.

A recent review in Current Diabetes Reports delves into the utility of sodium-glucose co-transporter-2 (SGLT2) inhibitors for patients with heart failure currently on other medications.

Patients with heart failure should be classified as high risk in light of the coronavirus disease 2019 (COVID-19) pandemic; they are thought to be more susceptible to the virus.

Patients with chronic heart failure and comorbid mental/behavioral disorders or diabetes had worse quality of life (QOL), according to a recent literature review.

At the 1-year mark, following their first myocardial infarction (MI, or heart attack), heart failure hospitalizations and all-cause mortality were higher among patients who also had cardiogenic shock vs those who did not.

Patients hospitalized for acute heart failure during the coronavirus disease 2019 (COVID-19) pandemic had more advanced disease and were more symptomatic, according to study results out of Australia.

The results of a recent study out of South Korea show that diet management education appeared more important to health care providers than it did their patients, while both expressed the significance of medication knowledge.

Patients testing positive for severe acute respiratory syndrome (SARS-CoV-2), the virus that causes coronavirus disease 2019, are presenting more often with signs of heart failure with preserved ejection fraction (HFpEF).

Over 12.5 years of follow-up, close to 10% of participants developed incident heart failure in a recent study that investigated possible differentiation of cardiovascular (CV) risk factors and biomarkers based on sex.

Increasing their numbers could help to improve both trial enrollment diversity and improve patient outcomes, according to research published in Circulation: Heart Failure.

Differences in heart failure mortality over the previous 2 decades can partially be explained by social determinants of health prevalent in the patients’ counties.

Widely accepted guidelines that patients with cardiac diseases still get at least 150 minutes of exercise each week may need to adjust their accelerometer data for patients with heart failure.

Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted this comparison study of patients with heart failure enrolled in Medicare fee-for-service plans (FFS) and MA plans.